苗玉迪,胡星星,李艳春,李程亮,赵乔佳杰.血清IL-17、IL-32、IL-33、IL-37联合检测对初治多发性骨髓瘤患者早期治疗反应性的预测价值[J].现代生物医学进展英文版,2022,(22):4279-4284. |
血清IL-17、IL-32、IL-33、IL-37联合检测对初治多发性骨髓瘤患者早期治疗反应性的预测价值 |
Predictive Value of Combined Detection of Serum IL-17, IL-32, IL-33 and IL-37 in Early Treatment Response of Primary Multiple Myeloma Patients |
Received:May 07, 2022 Revised:May 31, 2022 |
DOI:10.13241/j.cnki.pmb.2022.22.015 |
中文关键词: 多发性骨髓瘤 IL-17 IL-32 IL-33 IL-37 硼替佐米 治疗反应性 预测价值 |
英文关键词: Multiple myeloma IL-17 IL-32 IL-33 IL-37 Bortezomib Treatment response Predictive value |
基金项目:陕西省社会发展科技攻关项目(2015SF065) |
|
Hits: 783 |
Download times: 360 |
中文摘要: |
摘要 目的:探讨血清白细胞介素-17(IL-17)、白细胞介素-32(IL-32)、白细胞介素-33(IL-33)、白细胞介素-37(IL-37)联合检测对接受硼替佐米为基础一线治疗方案的初治多发性骨髓瘤(MM)患者早期治疗反应性的预测价值。方法:选择2018年7月至2021年3月期间陕西省人民医院收治的初治MM患者176例为研究对象,所有患者均接受以硼替佐米为基础一线的治疗方案,根据早期治疗反应性分为敏感组(142例)和非敏感组(34例);采用酶联免疫吸附法检测并比较两组血清IL-17、IL-32、IL-33、IL-37水平,并分析其联合检测对早期治疗反应性的预测价值。结果:敏感组治疗前血清IL-17、IL-32水平低于非敏感组,IL-33、IL-37水平高于非敏感组(P<0.05)。多因素logistic回归分析显示,年龄≥65岁、血清IL-17≥29.70 pg/mL、IL-32≥63.02 ng/L、肿瘤分期III期是早期治疗反应性的危险因素(P<0.05),IL-33>141.97 pg/mL、IL-37>69.17 ng/L是保护因素(P<0.05)。血清IL-17、IL-32、IL-33、IL-37联合检测预测早期治疗反应性的曲线下面积(AUC)为0.866(95%CI:0.801~0.972)。结论:年龄、肿瘤分期、血清IL-17、IL-32、IL-33、IL-37是MM患者早期治疗反应性的影响因素,联合检测血清IL-17、IL-32、IL-33、IL-37水平对接受硼替佐米为基础一线治疗方案的初治MM患者早期治疗反应性预测价值较高。 |
英文摘要: |
ABSTRACT Objective: To explore the predictive value of the combined detection of serum interleukin-17 (IL-17), interleukin-32 (IL-32), interleukin-33 (IL-33) and interleukin-37 (IL-37) in the early treatment response of primary multiple myeloma (MM) patients who received bortezomib based first-line treatment. Methods: 176 cases of primary MM patients in our hospital from July 2018 to March 2021 were selected as the research object. All patients received bortezomib based first-line treatment. They were divided into sensitive group (142 cases) and non sensitive group (34 cases) according to the early treatment response. The levels of serum IL-17, IL-32, IL-33 and IL-37 in the two groups were detected and compared by enzyme-linked immunosorbent assay, and the predictive value of their combined detection for early treatment response was analyzed. Results: Before treatment, the levels of serum IL-17 and IL-32 in sensitive group were lower than those in non sensitive group, and the levels of IL-33 and IL-37 were higher than those in non sensitive group (P<0.05). Multivariate Logistic regression analysis showed that age ≥ 65 years, serum IL-17 ≥ 29.70 pg/mL, IL-32 ≥ 63.02 ng/L, tumor stage III were the risk factors of early treatment response (P<0.05), IL-33 > 141.97 pg/mL, IL-37 > 69.17 ng/L were the protective factors (P<0.05). The area under the curve (AUC) of serum IL-17, IL-32, IL-33 and IL-37 combined detection in predicting early treatment response was 0.866 (95%CI: 0.801-0.972). Conclusion: Age, tumor stage, serum IL-17, IL-32, IL-33 and IL-37 are the influencing factors of early treatment response in MM patients. Combined detection of the levels of serum IL-17, IL-32, IL-33 and IL-37 has a high predictive value for early treatment response in MM patients receiving bortezomib based first-line treatment. |
View Full Text
View/Add Comment Download reader |
Close |
|
|
|